Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma.
Increasing evidence suggests a role for immunologic vaccination and therapy in the management of minimal residual myeloma. We have previously demonstrated a synergistic effect of combining the Th1 stimulating cytokine IL-12 with the co-stimulatory molecule CD80 in murine myeloma vaccination therapy. We reasoned that the efficacy of such treatment might be further improved by incorporating additional gene products which enhance the function of antigen presenting cells. Studies were therefore conducted with murine myeloma BM1 cells expressing Flt3L (membrane bound or soluble forms) or GM-CSF and the IL-12 x CD80 combination. Single agent and combined therapeutic approaches were explored. All gene-modified BM1 cells, except BM1/IL-12 x CD80, developed tumors when subcutaneously injected into BALB/c mice. As prophylactic tumor vaccines, the combined use of gene-modified BM1/sFlt3L+GM-CSF+IL-12 x CD80 was most effective, providing 100% protection against subsequent parental BM1 tumor challenge. By comparison, only partial protection was observed with any single gene-engineered tumor vaccine. Notably, IL-12 x CD80 coexpressing BM1 cell vaccines were the most effective therapeutic vaccine in a minimal disease model. Such protective vaccination was achieved by stimulation of lymphocyte proliferation and enhancement of cytotoxic lymphocyte activity.
Li
Z H
ZH
The Toronto General Hospital Research Institute and Medical Oncology, The Princess Margaret Hospital, McLaughlin Center for Molecular Medicine, Toronto, Ont., Canada.
Wen
X Y
XY
Mandelbaum
S
S
Falcioni
N
N
Hawley
T S
TS
Hawley
R G
RG
Stewart
A K
AK
D000276:Adjuvants, Immunologic / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D018122:B7-1 Antigen / Q000378:metabolism / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000378:metabolism / Q000627:therapeutic use*; D002455:Cell Division; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D018664:Interleukin-12 / Q000378:metabolism / Q000627:therapeutic use; D008024:Ligands; D008565:Membrane Proteins / Q000378:metabolism / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009101:Multiple Myeloma / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D012190:Retroviridae / Q000235:genetics; D013154:Spleen / Q000276:immunology; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured; D014611:Vaccination
D000276:Adjuvants, Immunologic; D018122:B7-1 Antigen; D019496:Cancer Vaccines; D008024:Ligands; D008565:Membrane Proteins; C084881:flt3 ligand protein; D018664:Interleukin-12; D016178:Granulocyte-Macrophage Colony-Stimulating Factor